Breaking News Instant updates and real-time market news.

MSFT

Microsoft

$57.42

-0.18 (-0.31%)

, FIT

Fitbit

$14.76

-0.08 (-0.54%)

16:14
10/03/16
10/03
16:14
10/03/16
16:14

Microsoft apparently winds down Band fitness tracker, ZDNet reports

Microsoft (MSFT) appears to have removed all references to its "Band" fitness tracker from its store, reports ZDNet. Additionally, the publication has received "various tips" that at least some members of the Band development team have exited, with ZDNet's sources adding that Microsoft plans to phase out its fitness bands and has no plans for a Band 3 any time soon. Responding to the report, a Microsoft spokesperson told the publication that "we have sold through our existing Band 2 inventory and have no plans to release another Band device this year. We... will continue to invest in the Microsoft Health platform." Other publicly traded companies in the fitness tracker space include Fitbit (FIT), Garmin (GRMN) and Apple (AAPL). Reference Link

MSFT

Microsoft

$57.42

-0.18 (-0.31%)

FIT

Fitbit

$14.76

-0.08 (-0.54%)

GRMN

Garmin

$48.24

0.13 (0.27%)

AAPL

Apple

$112.52

-0.53 (-0.47%)

  • 03

    Oct

  • 16

    Oct

  • 23

    Oct

  • 25

    Oct

  • 26

    Oct

  • 14

    Nov

  • 30

    Nov

  • 08

    Dec

  • 13

    Mar

MSFT Microsoft
$57.42

-0.18 (-0.31%)

09/13/16
PACS
09/13/16
NO CHANGE
PACS
Microsoft cloud revenue could triple in four years, says Pacific Crest
Pacific Crest analyst Brent Bracelin says that Microsoft's cloud revenue "has the potential to triple in four years to $40B plus." The analyst thinks that the company could use artificial technology to create new "smart applications." He says the shares could exceed their all-time high of $58.72 and keeps a $65 price target and Overweight rating on the stock.
09/26/16
CANT
09/26/16
NO CHANGE
Target $42
CANT
Buy
Yelp takeout chances increased with share conversion, says Cantor
Yelp's (YELP) conversion of Class B super-voting shares into regular Class A shares late last week increases the company's takeout potential, Cantor Fitzgerald analyst Youssef Squali tells investors in a research note. Yelp, especially following recent improvements in the underlying growth fundamentals of the business, has become "an easier, and more likely" acquisition target, the analyst contends. The analyst views Facebook (FB), Priceline (PCLN), TripAdvisor (TRIP) and Microsoft (MSFT) as potential acquirers of Yelp. Squali estimates Yelp could be worth $53 per share in a takeout. He keeps a Buy rating on the stock with a $42 price target. The stock is up 2% to $40.35 in early trading.
09/23/16
RHCO
09/23/16
NO CHANGE
RHCO
Buy
SunTrust says Twitter would help Salesforce deal with Microsoft
SunTrust analyst John Rizzuto believes a potential acquisition of Twitter (TWTR) could give Salesforce (CRM) a "strong external social platform" that can enhance its ecosystem while addressing the longer-term threat from Microsoft (MSFT). With less than $2B of cash on hand, Salesforce would need to raise much of the required capital as equity with a smaller debt component, Rizzuto tells investors in a research note. The analyst remains positive on Salesforce shares with a Buy rating. CNBC's David Faber reported earlier today that Twitter is getting closer to a sale and he named Salesforce as one of the potential suitors. Salesforce is down 5% to $70.69 while Twitter is up 19% to $22.12 in afternoon trading.
09/06/16
RHCO
09/06/16
NO CHANGE
Target $18
RHCO
Neutral
SunTrust sees 'limited' list of Twitter suitors, says activist action unlikely
SunTrust analyst Robert Peck reiterated his belief that Twitter (TWTR) is unlikely to sell itself in 2016 in a new note to investors, but noted that investors have asked him who would be interested if Twitter were open to a sale. While giving his opinion on potential acquirers - which he sees possibly including Google (GOOG), Facebook (FB), Apple (AAPL), Amazon (AMZN), Microsoft (MSFT), AT&T (T), Verizon (VZ), Disney (DIS), Fox (FOXA), and Alibaba (BABA) - Peck said the company's high price and "unique" asset limit the potential buyers and gave his view that a PE buyer is highly unlikely given the company's lack of free cash flow. Additionally, Peck thinks activist action at Twitter seems "extremely unlikely" despite "unsubstantiated investor conjecture" and media reports. The analyst keeps Neutral rating and $18 price target on Twitter shares.
FIT Fitbit
$14.76

-0.08 (-0.54%)

09/29/16
MZHO
09/29/16
NO CHANGE
MZHO
Fitbit Charge 2 checks remain strong, pullback unwarranted, says Mizuho
Mizuho's checks indicate Fitbit's Charge 2 sell through remains strong with favorable reviews, despite investor concerns. The firm's analyst views the pullback in Fitbit shares as unwarranted, especially since Q3 guidance assume minimal unit sales, and expects the Charge 2 to compete well and serve as a catalyst for Holiday season into Spring 2017. Mizuho continues to believe in Fitbit's long-term opportunity to maintain dominant share with in the increasingly growing global market for wearables while pursing opportunities in the healthcare industry.
09/29/16
MZHO
09/29/16
NO CHANGE
MZHO
Fitbit shares defended at Mizuho
09/29/16
09/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Coca-Cola (KO) downgraded to Hold from Buy at Stifel with analyst Mark Swartzberg saying that Coca-Cola's and Pepsi's organic EPS growth appears to be similar, but he believes that Pepsi is less vulnerable to foreign exchange fluctuations. 2. Fitbit (FIT) downgraded to Underweight from Sector Weight at Pacific Crest analyst Brad Erickson citing his channel checks which indicated that Charge 2, the company's flagship holiday product, is off to a slow start. 3. Discovery (DISCA) downgraded to Market Perform from Outperform at Barrington with analyst James Goss saying that Brexit and sports costs are dragging on its international results and foreign exchange tailwinds are moderating in many geographies. 4. Sonus (SONS) downgraded to Underperform from Market Perform at Cowen with analyst Paul Silverstein saying the firm's industry checks uncovered operational challenges and ongoing employee and executive churn. 5. Alcobra (ADHD) downgraded to Hold from Buy at Cantor and to Perform from Outperform at Oppenheimer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
PACS
09/29/16
DOWNGRADE
PACS
Underweight
Pacific Crest cuts Fitbit to sell, sees share downside to $11
Pacific Crest analyst Brad Erickson downgraded Fitbit (FIT) to Underweight from Sector Weight after his channel checks indicated that Charge 2, the company's flagship holiday product, is off to a slow start. Underweight is Pacific Crest's equivalent of a sell rating. Charge 2 inventory is accumulating in the channel and sell-through is below initial Blaze/Alta levels, Erickson tells investors in a research note. The analyst continues to believe that a large portion of Fitbit owners stop using the device within months. Further, he views the corporate wellness deal between Aetna (AET) and Apple (AAPL) as a "substantial negative" for Fitbit. Erickson sees downside to $11 for shares of Fitbit. The stock closed yesterday up 17c to $16.70.
GRMN Garmin
$48.24

0.13 (0.27%)

08/24/16
GSCO
08/24/16
DOWNGRADE
Target $46
GSCO
Sell
Garmin downgraded to Sell from Neutral at Goldman
Goldman analyst Simona Jankowski downgraded Garmin to Sell citing valuation and near peak multiple. The analyst expects the key Fitness/Outdoor segment growth to slow in Q2 to 7% in 2017 from 29% in Q2 2016 resulting in share underperformance. Jankowski sees several negative catalysts over the next few months that include increased competitor product launches, increased competition from new emerging consumer electronics categories, and difficult comps.
09/08/16
BERN
09/08/16
NO CHANGE
BERN
Impact of Apple Watch likely to be 'limited' in near-term, says Bernstein
After Apple (AAPL) announced changes to its Apple Watch, Bernstein analyst A.M. Sacconaghi, Jr. says that the device's "relatively high price, continued tepid battery life and the absence of unique health monitoring capabilities will likely limit its overall impact near-term." Fitbit (FIT) and Garmin (GRMN) market watches that compete with Apple Watch. The analyst keeps a $125 price target and Outperform rating on Apple.
08/30/16
GSCO
08/30/16
NO CHANGE
GSCO
Sell
Garmin's Fitness/Outdoor sales to decelerate, says Goldman
Goldman analyst Simona Jankowski expects Garmin's (GRMN) Fitness/Outdoor sales to decelerate in 2H 2016/2017, leading to share underperformance, following Fitbit's new product launches. The analyst notes increasing direct competition in wearables and share of wallet competition from new consumer categories such as VR headsets, cameras and drones for the holidays, and reiterates his Sell rating on Garmin.
08/24/16
08/24/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Garmin (GRMN) downgraded to Sell from Neutral at Goldman with analyst Simona Jankowski citing valuation and near peak multiple. 2. Express (EXPR) downgraded to Hold from Buy at Deutsche Bank. 3. New Media (NEWM) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying New Media bulls see $1B of M&A by year end, further synergies, organic revenues stabilizing in the fourth quarter of 2017, and a robust, sustainable dividend. However, Bazinet believes the bear case is more likely with no additional M&A, top-line trends that fall short of stable revenues by Q4 of 2017, and growing investor anxiety about the sustainability of the dividend. 4. Nordson (NDSN) downgraded to Perform from Outperform at Oppenheimer with analyst Christopher Glynn citing valuation. 5. Westfield Financial (WFD) downgraded to Underperform from Neutral at Macquarie citing disappointing first half 2016 results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AAPL Apple
$112.52

-0.53 (-0.47%)

09/29/16
LEHM
09/29/16
NO CHANGE
Target $61
LEHM
Overweight
Western Digital is a new Top Pick in IT Hardware at Barclays
Barclays analyst Mark Moskowitz recommends investors build positions in Western Digital (WDC) and named it his new Top Pick in IT Hardware, removing Apple (AAPL). Western Digital issued a positive September quarter financial update citing a favorable mix in both HDD and SSD, and particularly good pricing conditions in NAND flash, the analyst wrote. Moskowitz believes the company's commentary is positive for investor sentiment and added it to the top spot given improving end markets, reduced industry manufacturing capacity, and potential for further operational synergies. He recommends investors build or add positions in Western Digital as gross margins should trend upward in the near- to mid-term. Moskowitz rates Western Digital an Overweight with a $61 price target on shares.
09/29/16
LEHM
09/29/16
NO CHANGE
Target $114
LEHM
Overweight
Barclays removes Apple as Top Pick after trimming global smartphone forecast
Barclays analyst Mark Moskowitz removed the firm's Top Pick designation on Apple (AAPL) shares after the firm trimmed its 2016 smartphone revenue and unit growth estimates, saying that the firm's research is not pointing to any major improvement in smartphone units beyond initial channel fill for the new iPhones and Samsung (SSNLF) Galaxy products. The firm now estimates a decline of 2.9% in smartphone revenue and growth of 2.6% in smartphone units, versus its prior forecast for a revenue decline of 0.7% and unit growth of 3.7% in 2016. Moskowitz, who thinks Apple shares may see near-term choppiness after their recent run-up, keeps an Overweight rating on the stock but lowered his price target to $114 from $115.
09/30/16
SBSH
09/30/16
NO CHANGE
Target $130
SBSH
Buy
Apple price target raised to $130 from $120 at Citi
Citi analyst Jim Suva raised his price target for Apple shares to $130 from $120 and keeps a Buy rating on the name. The stock closed yesterday down $1.77 to $112.18. U.S., Canada, European and Asian store checks indicate iPhone 7 demand at launch appears strong, Suva tells investors in a research note. Supply remains a limiting factor with many stores having received very limited supply of the iPhone 7 and in some cases only to suffice demand from preorders, the analyst adds. Suva raised his iPhone estimate for the December quarter to 79.4M units, above the consensus of 75M units.
10/03/16
PIPR
10/03/16
NO CHANGE
Target $151
PIPR
Overweight
Apple checks show iPhone 7 inventory still constrained, says Piper Jaffray
Piper Jaffray analyst Gene Munster said his checks of 134 Apple Stores in the U.S. showed that iPhone 7 and iPhone 7 Plus inventory levels are improved, but still constrained, and that supply appears even tighter in China. The limited supply of the iPhone 7 Plus should bode well for the December quarter outlook, adds Munster, who keeps an Overweight rating and $151 price target on Apple shares.

TODAY'S FREE FLY STORIES

02:50
12/06/16
12/06
02:50
12/06/16
02:50
General news
FX Update: Most dollar pairings remained with Monday's ranges »

FX Update: Most dollar…

JUNO

Juno Therapeutics

$20.42

-0.01 (-0.05%)

23:25
12/05/16
12/05
23:25
12/05/16
23:25
Conference/Events
Juno Therapeutics to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

22:55
12/05/16
12/05
22:55
12/05/16
22:55
Conference/Events
Seattle Genetics to hold an investor reception »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

GNMSF

Genmab

$171.98

3.9767 (2.37%)

22:30
12/05/16
12/05
22:30
12/05/16
22:30
Conference/Events
Genmab to hold data review meeting »

Management discusses data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

TGTX

TG Therapeutics

$5.70

0.2 (3.64%)

22:25
12/05/16
12/05
22:25
12/05/16
22:25
Conference/Events
TG Therapeutics to hold an investor and analyst reception »

In connection with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

RHHBY

Roche

$27.67

0.47 (1.73%)

20:25
12/05/16
12/05
20:25
12/05/16
20:25
Conference/Events
Roche to hold an analyst meeting »

Analyst Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

AZO

AutoZone

$776.42

-7.32 (-0.93%)

, HDS

HD Supply

$39.75

0.67 (1.71%)

20:25
12/05/16
12/05
20:25
12/05/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AZO

AutoZone

$776.42

-7.32 (-0.93%)

HDS

HD Supply

$39.75

0.67 (1.71%)

MIK

Michaels

$24.31

0.34 (1.42%)

TOL

Toll Brothers

$30.47

1.15 (3.92%)

BOBE

Bob Evans

$46.77

1.05 (2.30%)

CONN

Conn's

$11.20

0.4 (3.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 14

    Dec

  • 09

    Jan

GDDY

GoDaddy

$34.74

1.45 (4.36%)

20:14
12/05/16
12/05
20:14
12/05/16
20:14
Hot Stocks
GoDaddy acquires WP Curve »

WP Curve announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$74.99

0.9 (1.21%)

20:10
12/05/16
12/05
20:10
12/05/16
20:10
Earnings
Belden sees FY17 adjusted EPS $5.00-$5.25, consensus $5.23 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGMO

Sangamo

19:39
12/05/16
12/05
19:39
12/05/16
19:39
Hot Stocks
Sangamo reports preclinical, manufacturing data on SB-525, says IND on track »

Sangamo BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

, BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

19:38
12/05/16
12/05
19:38
12/05/16
19:38
Hot Stocks
Seattle Genetics, Bristol-Myers: Data supports ADCETRIS, Opdivo combo »

Seattle Genetics (SGEN)…

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

LGIH

LGI Homes

$32.34

0.45 (1.41%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
LGI Homes reports November home closings up 28.9% y/y »

LGI Homes announced 321…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$116.56

-1.07 (-0.91%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
Celgene reports analysis of three CC-486 studies »

Celgene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BLUE

bluebird bio

$72.15

2.4 (3.44%)

19:35
12/05/16
12/05
19:35
12/05/16
19:35
Hot Stocks
bluebird bio provides updates on HSC gene therapy programs »

bluebird bio provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$49.88

-7.09 (-12.45%)

19:33
12/05/16
12/05
19:33
12/05/16
19:33
Hot Stocks
Agios 'encouraged' by durable clinical activity of AG-120 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$60.25

-0.88 (-1.44%)

19:31
12/05/16
12/05
19:31
12/05/16
19:31
Hot Stocks
Merck: KEYNOTE-087 trial data shows oORR of 69%, CRR of 22.4% »

Merck announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 08

    Mar

TWX

Time Warner

$93.34

-0.46 (-0.49%)

, T

AT&T

$38.63

0.02 (0.05%)

19:29
12/05/16
12/05
19:29
12/05/16
19:29
Periodicals
Time Warner 'struggling to expand' HBO Now, NY Post says »

Time Warner (TWX) is…

TWX

Time Warner

$93.34

-0.46 (-0.49%)

T

AT&T

$38.63

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

BP

BP

, REPYY

Repsol

$13.88

0.25 (1.83%)

19:18
12/05/16
12/05
19:18
12/05/16
19:18
Periodicals
BP acquires Repsol stake in Indonesia LNG plant, Reuters says »

BP (BP) has purchased…

BP

BP

REPYY

Repsol

$13.88

0.25 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSUF

Fosun

19:12
12/05/16
12/05
19:12
12/05/16
19:12
Hot Stocks
Liberty Mutual to acquire Fosun subsidiary Ironshore for roughly $3B »

Liberty Mutual Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$49.75

-0.06 (-0.12%)

, YHOO

Yahoo

$40.20

0.13 (0.32%)

18:54
12/05/16
12/05
18:54
12/05/16
18:54
Periodicals
AOL CEO 'cautiously optimistic' Verizon-Yahoo deal will go through, WSJ says »

AOL CEO Tim Armstrong…

VZ

Verizon

$49.75

-0.06 (-0.12%)

YHOO

Yahoo

$40.20

0.13 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 24

    Jan

TUWOY

Tullow Oil

$2.06

0.109 (5.58%)

18:46
12/05/16
12/05
18:46
12/05/16
18:46
Downgrade
Tullow Oil rating change  »

Tullow Oil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$22.15

0.75 (3.50%)

18:43
12/05/16
12/05
18:43
12/05/16
18:43
Hot Stocks
Breaking Hot Stocks news story on Guaranty Bancorp »

Castle Creek raises stake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$20.48

-0.18 (-0.87%)

18:41
12/05/16
12/05
18:41
12/05/16
18:41
Syndicate
Atkore files to sell 8M shares of common stock for holders »

The offering is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$107.42

-0.8 (-0.74%)

18:38
12/05/16
12/05
18:38
12/05/16
18:38
Hot Stocks
United Technologies CEO: No quid pro quo on taxes in Carrier deal with Trump »

Says Carrier agreement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPDN

Professional Diversity Network

$9.75

-0.01 (-0.10%)

18:37
12/05/16
12/05
18:37
12/05/16
18:37
Hot Stocks
Breaking Hot Stocks news story on Professional Diversity Network »

North Star cuts passive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.